Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jason Hafron MD

Jason Hafron MD

Chief Medical Officer and Director of Clinical Research, Michigan Institute of Urology (MIU); Professor of Urology, William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan

Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology (MIU). Dr. Hafron is a Professor of Urology at the William Beaumont School of Medicine, Oakland University, Royal Oak, Michigan. He is experienced in all areas of adult urology, specializing in the minimally invasive treatment of cancers involving the prostate, kidney and bladder utilizing robotic surgery.

Disclosures

Astellas Pharma Inc; Consultant/Advisor, Meeting participant/lecturer. Scientific Study/Trial

Amgen Inc; Meeting participant/lecturer.

Bayer; Meeting participant/lecturer, Scientific Study/Trial

Blue Earth Diagnostics; Meeting participant/lecturer

Dendreon Pharmaceuticals LLC; Consultant/Advisor, Meeting participant/lecturer Scientific Study/Trial

Janssen Biotech Inc; Consultant/Advisor, Meeting participant/lecturer, Scientific Study/Trial

Lipella Pharmaceuticals LLC; Scientific Study/Trial

Lantheus, Meeting participant/lecturer

Merck & Co. Inc.; Meeting participant/lecturer, Scientific Study/Trial

miR Scientific Inc.; Scientific Study/Trial

Myriad Genetics Inc; Consultant/Advisor, Meeting participant/lecturer, Scientific Study/Trial

Myovant Sciences Inc; Consultant/Advisor, Meeting participant/lecturer

Nucleix; Scientific Study/Trial

Pfizer Inc; Consultant/Advisor; Meeting participant/lecturer, Scientific Study/Trial

Procept-Biorobotic; Meeting participant/lecturer,

Progenics Pharmaceuticals, Inc.; Meeting participant/lecturer

Tolmar Pharmaceuticals Inc; Meeting participant/lecturer

Urogen Pharma Inc; Meeting participant/lecturer

Promaxo; Consultant/Advisor

Lynx DX; Consultant/Advisor

Recent Contributions to PracticeUpdate:

  1. Predicting the Optimal Number of MRI-Targeted Biopsy Cores Required for Accurate Diagnosis in Patients With Possible Prostate Cancer
  2. Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy With Four Cores vs Target Saturation Biopsy With Nine Cores in Transperineal Prostate Fusion Biopsy
  3. Outcomes of Single-Port Robotic Transvesical Partial Prostatectomy in Patients With Localized Prostate Cancer

Recently Updated